Metformina + Sitagliptina Pharmakern (Metformin Hydrochloride, Sitagliptin)

Metformina + Sitagliptina Pharmakern is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation.

• Type 2 diabetes mellitus: improves overall glycemic control when added to diet, exercise and existing therapy.
• Inadequate response to metformin monotherapy: provides additional glucose‑lowering effect through complementary mechanisms.
• Patients requiring both insulin sensitization and incretin enhancement: offers dual action to reduce fasting and post‑prandial glucose levels.

• Metformina + Sitagliptina combines metformin, a biguanide that suppresses hepatic gluconeogenesis and increases peripheral insulin sensitivity, with sitagliptin, a selective dipeptidyl peptidase‑4 (DPP‑4) inhibitor that prevents degradation of incretin hormones (GLP‑1 and GIP). The resulting rise in active incretins enhances glucose‑dependent insulin secretion and reduces glucagon release, while metformin’s actions lower basal glucose production, providing complementary control of fasting and post‑prandial blood glucose.

Metformina + Sitagliptina may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild gastrointestinal upset that often resolves with continued use.
• Diarrhea: loose stools that may be transient.
• Headache: mild to moderate head pain.
• Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal accumulation of lactate, requiring immediate medical attention.
• Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain.
• Severe hypersensitivity reactions: including skin rash, angioedema or anaphylaxis.

When prescribing Metformina + Sitagliptina, clinicians should consider several safety precautions to minimize risk.

• Renal function: assess baseline renal function and monitor periodically, as metformin accumulation can occur in impairment.
• Hepatic impairment: use with caution in patients with liver disease due to increased risk of lactic acidosis.
• Heart failure: avoid in patients with unstable or severe congestive heart failure.
• Pregnancy and breastfeeding: safety not established; weigh potential benefits against risks.
• Drug interactions: review concomitant medications for potential interactions affecting renal clearance or hypoglycemia risk.
• Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Metformina + Sitagliptina can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Concomitant use with insulin or sulfonylureas: may cause severe hypoglycemia.
• Intravenous iodinated contrast agents: can impair renal function and increase metformin exposure.
• Cimetidine: may raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely)

• Loop or thiazide diuretics: may affect renal function, requiring dose adjustment.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.
• Rifampin: may reduce sitagliptin concentrations, potentially decreasing glucose‑lowering effect.